Phigenix Fights $2.2M Atty Fee Bid In Cancer Drug IP Row
Phigenix Inc. is fighting Genentech Inc.'s request for more than $2.2 million in attorneys' fees after beating a patent infringement suit in California federal court over the breast cancer drug Kadcyla....To view the full article, register now.
Already a subscriber? Click here to view full article